Which has higher valuation & earnings, CHE or MEDP?

Medpace has lower revenue, but higher earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.54B 2.33 $265.24M $18.35 24.35 Medpace $2.53B 5.27 $451.12M $15.91 29.34

Is CHE or MEDP more profitable?

Medpace has a net margin of 17.19% compared to Chemed's net margin of 10.23%. Medpace's return on equity of 120.89% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% Medpace 17.19% 120.89% 24.79%

Does the media refer more to CHE or MEDP?

In the previous week, Medpace had 29 more articles in the media than Chemed. MarketBeat recorded 40 mentions for Medpace and 11 mentions for Chemed. Chemed's average media sentiment score of 1.15 beat Medpace's score of 0.32 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 13 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, DGX or CHE?

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 2.05 $992M $9.05 22.61 Chemed $2.54B 2.33 $265.24M $18.35 24.35

Is DGX or CHE more profitable?

Chemed has a net margin of 10.23% compared to Quest Diagnostics' net margin of 9.07%. Chemed's return on equity of 27.18% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.07% 15.60% 7.06% Chemed 10.23% 27.18% 17.38%

Does the media prefer DGX or CHE?

In the previous week, Quest Diagnostics had 10 more articles in the media than Chemed. MarketBeat recorded 21 mentions for Quest Diagnostics and 11 mentions for Chemed. Chemed's average media sentiment score of 1.15 beat Quest Diagnostics' score of 1.06 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 16 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, LH or CHE?

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.59 $876.50M $11.29 24.00 Chemed $2.54B 2.33 $265.24M $18.35 24.35

Is LH or CHE more profitable?

Chemed has a net margin of 10.23% compared to Labcorp's net margin of 6.66%. Chemed's return on equity of 27.18% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Labcorp 6.66% 16.29% 7.62% Chemed 10.23% 27.18% 17.38%

Does the media prefer LH or CHE?

In the previous week, Chemed had 3 more articles in the media than Labcorp. MarketBeat recorded 11 mentions for Chemed and 8 mentions for Labcorp. Labcorp's average media sentiment score of 1.21 beat Chemed's score of 1.15 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DVA or CHE?

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.93 $746.80M $10.78 18.39 Chemed $2.54B 2.33 $265.24M $18.35 24.35

Is DVA or CHE more profitable?

Chemed has a net margin of 10.23% compared to DaVita's net margin of 5.65%. Chemed's return on equity of 27.18% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Chemed 10.23% 27.18% 17.38%

Does the media favor DVA or CHE?

In the previous week, Chemed had 2 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Chemed and 9 mentions for DaVita. DaVita's average media sentiment score of 1.25 beat Chemed's score of 1.15 indicating that DaVita is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CHE or CRVL?

Chemed presently has a consensus target price of $501.50, indicating a potential upside of 12.23%. Given Chemed's stronger consensus rating and higher possible upside, research analysts clearly believe Chemed is more favorable than CorVel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 CorVel 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CHE or CRVL?

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.54B 2.33 $265.24M $18.35 24.35 CorVel $958.53M 3.24 $110.34M $2.14 28.59

Is CHE or CRVL more profitable?

CorVel has a net margin of 11.51% compared to Chemed's net margin of 10.23%. CorVel's return on equity of 29.92% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% CorVel 11.51% 29.92% 17.68%

Does the media favor CHE or CRVL?

In the previous week, Chemed had 9 more articles in the media than CorVel. MarketBeat recorded 11 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.15 beat CorVel's score of 0.00 indicating that Chemed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorVel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Chemed (CHE) Competitors

$446.20 +7.07 (+1.61%)

As of 04:00 PM Eastern

Compare

CHE vs. MEDP, DGX, LH, DVA, and CRVL

Should you buy Chemed stock or one of its competitors? MarketBeat compares Chemed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemed include Medpace (MEDP), Quest Diagnostics (DGX), Labcorp (LH), DaVita (DVA), and CorVel (CRVL).

How does Chemed compare to Medpace?

Chemed (NYSE:CHE) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

95.8% of Chemed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 3.3% of Chemed shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Chemed currently has a consensus price target of $501.50, suggesting a potential upside of 12.23%. Medpace has a consensus price target of $467.08, suggesting a potential upside of 0.06%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Medpace has lower revenue, but higher earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.54B	2.33	$265.24M	$18.35	24.35
Medpace	$2.53B	5.27	$451.12M	$15.91	29.34

Medpace has a net margin of 17.19% compared to Chemed's net margin of 10.23%. Medpace's return on equity of 120.89% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.23%	27.18%	17.38%
Medpace	17.19%	120.89%	24.79%

In the previous week, Medpace had 29 more articles in the media than Chemed. MarketBeat recorded 40 mentions for Medpace and 11 mentions for Chemed. Chemed's average media sentiment score of 1.15 beat Medpace's score of 0.32 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	13 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

Medpace beats Chemed on 10 of the 16 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.8% of Chemed shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.05	$992M	$9.05	22.61
Chemed	$2.54B	2.33	$265.24M	$18.35	24.35

Quest Diagnostics presently has a consensus target price of $216.58, indicating a potential upside of 5.83%. Chemed has a consensus target price of $501.50, indicating a potential upside of 12.23%. Given Chemed's higher probable upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Quest Diagnostics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Chemed has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.7%. Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.5%. Quest Diagnostics pays out 38.0% of its earnings in the form of a dividend. Chemed pays out 13.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years and Chemed has increased its dividend for 16 consecutive years.

In the previous week, Quest Diagnostics had 10 more articles in the media than Chemed. MarketBeat recorded 21 mentions for Quest Diagnostics and 11 mentions for Chemed. Chemed's average media sentiment score of 1.15 beat Quest Diagnostics' score of 1.06 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	16 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed has a net margin of 10.23% compared to Quest Diagnostics' net margin of 9.07%. Chemed's return on equity of 27.18% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
Chemed	10.23%	27.18%	17.38%

Summary

Chemed beats Quest Diagnostics on 12 of the 19 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Labcorp (NYSE:LH) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.5%. Labcorp pays out 25.5% of its earnings in the form of a dividend. Chemed pays out 13.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years.

Labcorp presently has a consensus target price of $308.00, suggesting a potential upside of 13.66%. Chemed has a consensus target price of $501.50, suggesting a potential upside of 12.23%. Given Labcorp's stronger consensus rating and higher probable upside, equities analysts plainly believe Labcorp is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 95.8% of Chemed shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Chemed had 3 more articles in the media than Labcorp. MarketBeat recorded 11 mentions for Chemed and 8 mentions for Labcorp. Labcorp's average media sentiment score of 1.21 beat Chemed's score of 1.15 indicating that Labcorp is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed has a net margin of 10.23% compared to Labcorp's net margin of 6.66%. Chemed's return on equity of 27.18% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
Chemed	10.23%	27.18%	17.38%

Labcorp has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Chemed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.59	$876.50M	$11.29	24.00
Chemed	$2.54B	2.33	$265.24M	$18.35	24.35

Summary

Chemed beats Labcorp on 10 of the 19 factors compared between the two stocks.

How does Chemed compare to DaVita?

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

DaVita presently has a consensus price target of $199.17, indicating a potential upside of 0.49%. Chemed has a consensus price target of $501.50, indicating a potential upside of 12.23%. Given Chemed's higher probable upside, analysts plainly believe Chemed is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.93	$746.80M	$10.78	18.39
Chemed	$2.54B	2.33	$265.24M	$18.35	24.35

90.1% of DaVita shares are owned by institutional investors. Comparatively, 95.8% of Chemed shares are owned by institutional investors. 1.5% of DaVita shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Chemed had 2 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Chemed and 9 mentions for DaVita. DaVita's average media sentiment score of 1.25 beat Chemed's score of 1.15 indicating that DaVita is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Chemed has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Chemed has a net margin of 10.23% compared to DaVita's net margin of 5.65%. Chemed's return on equity of 27.18% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Chemed	10.23%	27.18%	17.38%

Summary

Chemed beats DaVita on 10 of the 16 factors compared between the two stocks.

How does Chemed compare to CorVel?

Chemed (NYSE:CHE) and CorVel (NASDAQ:CRVL) are both mid-cap health care services companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Chemed has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, CorVel has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

CorVel has a net margin of 11.51% compared to Chemed's net margin of 10.23%. CorVel's return on equity of 29.92% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.23%	27.18%	17.38%
CorVel	11.51%	29.92%	17.68%

Chemed presently has a consensus target price of $501.50, indicating a potential upside of 12.23%. Given Chemed's stronger consensus rating and higher possible upside, research analysts clearly believe Chemed is more favorable than CorVel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CorVel	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Chemed has higher revenue and earnings than CorVel. Chemed is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.54B	2.33	$265.24M	$18.35	24.35
CorVel	$958.53M	3.24	$110.34M	$2.14	28.59

95.8% of Chemed shares are owned by institutional investors. Comparatively, 51.4% of CorVel shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 44.6% of CorVel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Chemed had 9 more articles in the media than CorVel. MarketBeat recorded 11 mentions for Chemed and 2 mentions for CorVel. Chemed's average media sentiment score of 1.15 beat CorVel's score of 0.00 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorVel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Chemed beats CorVel on 9 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$5.93B	$5.68B	$6.48B	$23.06B
Dividend Yield	0.56%	1.56%	2.67%	4.10%
P/E Ratio	24.35	31.56	24.57	30.54
Price / Sales	2.33	25.51	531.63	12.85
Price / Cash	17.90	15.94	26.99	18.46
Price / Book	6.46	3.11	10.53	4.65
Net Income	$265.24M	$218.81M	$3.56B	$1.07B
7 Day Performance	7.00%	1.52%	-0.88%	-0.70%
1 Month Performance	5.27%	-0.94%	1.45%	0.07%
1 Year Performance	-18.63%	10.19%	21.50%	21.50%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	4.0641 of 5 stars	$446.85 +1.8%	$501.50 +12.2%	-21.8%	$5.93B	$2.54B	24.35	15,811	Positive News Analyst Downgrade
MEDP Medpace	2.0719 of 5 stars	$451.47 +1.0%	$467.08 +3.5%	+54.4%	$12.77B	$2.68B	28.38	6,200
DGX Quest Diagnostics	4.3149 of 5 stars	$192.26 -1.4%	$216.58 +12.7%	+12.9%	$21.57B	$11.04B	21.24	57,000	Positive News Insider Trade
LH Labcorp	4.2056 of 5 stars	$256.87 -1.2%	$308.00 +19.9%	+3.0%	$21.32B	$14.14B	22.75	71,000	Positive News
DVA DaVita	4.2678 of 5 stars	$190.28 -2.1%	$199.17 +4.7%	+39.1%	$12.48B	$13.64B	17.65	78,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors